Valion Bio, Inc. Cost of Revenue
Valion Bio, Inc. (VBIO) reported Cost of Revenue of $32.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2025-08-14
- Valion Bio, Inc. cost of revenue for the quarter ending 2025-06-30 was $32.00K, a 70.91% decline year-over-year.
- Valion Bio, Inc. cost of revenue for the quarter ending 2025-03-31 was $20.00K, a 88.02% decline year-over-year.
- Valion Bio, Inc. cost of revenue for the quarter ending 2024-12-31 was $419.00K, a 19.03% increase year-over-year.
- Valion Bio, Inc. cost of revenue for the quarter ending 2024-09-30 was $82.00K, a 52.87% decline year-over-year.
- Valion Bio, Inc. cost of revenue for fiscal 2024 was $778.00K, a 12.49% decline from fiscal 2023.
- Valion Bio, Inc. cost of revenue for fiscal 2023 was $889.00K, a 42.31% decline from fiscal 2022.
- Valion Bio, Inc. cost of revenue for fiscal 2022 was $1.54M, a 19.00% increase from fiscal 2021.
- Valion Bio, Inc. cost of revenue for fiscal 2021 was $1.29M.
| Period end | Cost of Revenue 1 month | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | $32.00K 10-Q · filed 2025-08-14 | $52.00K 10-Q · filed 2025-08-14 | $471.00K derived: sum of 3 quarters · filed 2025-08-14 | $553.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2025-03-31 | $20.00K 10-Q · filed 2025-05-15 | $439.00K derived: sum of 2 quarters · filed 2025-05-15 | $521.00K derived: sum of 3 quarters · filed 2025-05-15 | $631.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-12-31 | $419.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $501.00K derived: sum of 2 quarters · filed 2025-03-21 | $611.00K derived: sum of 3 quarters · filed 2025-08-14 | $778.00K 10-K · filed 2025-03-21 | |
| 2024-09-30 | $82.00K 10-Q · filed 2024-11-14 | $192.00K derived: sum of 2 quarters · filed 2025-08-14 | $359.00K 10-Q · filed 2024-11-14 | $711.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-06-30 | $110.00K 10-Q · filed 2025-08-14 | $277.00K 10-Q · filed 2025-08-14 | $629.00K derived: sum of 3 quarters · filed 2025-08-14 | $803.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $167.00K 10-Q · filed 2025-05-15 | $519.00K derived: sum of 2 quarters · filed 2025-05-15 | $693.00K derived: sum of 3 quarters · filed 2025-05-15 | $793.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $526.00K derived: sum of 2 quarters · filed 2025-03-21 | $626.00K derived: sum of 3 quarters · filed 2025-03-21 | $889.00K 10-K · filed 2025-03-21 | |
| 2023-09-30 | $174.00K 10-Q · filed 2024-11-14 | $274.00K derived: sum of 2 quarters · filed 2024-11-14 | $537.00K 10-Q · filed 2024-11-14 | $902.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-14 | $363.00K 10-Q · filed 2024-08-14 | $728.00K derived: sum of 3 quarters · filed 2024-08-14 | $1.14M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $263.00K 10-Q · filed 2024-05-15 | $628.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.04M derived: sum of 3 quarters · filed 2024-05-15 | $1.45M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $779.00K derived: sum of 2 quarters · filed 2024-03-25 | $1.18M derived: sum of 3 quarters · filed 2024-03-25 | $1.54M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $414.00K 10-Q · filed 2023-11-14 | $817.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.18M 10-Q · filed 2023-11-14 | $1.57M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $403.00K 10-Q · filed 2023-08-14 | $760.00K 10-Q · filed 2023-08-14 | $1.15M derived: sum of 3 quarters · filed 2023-08-14 | $1.46M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $358.00K 10-Q · filed 2023-05-15 | $749.00K derived: sum of 2 quarters · filed 2023-05-15 | $1.05M derived: sum of 3 quarters · filed 2023-05-15 | $1.35M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2022-01-31 | $358.00K 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $391.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $694.00K derived: sum of 2 quarters · filed 2023-03-31 | $995.00K derived: sum of 3 quarters · filed 2023-03-31 | $1.29M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $303.00K 10-Q · filed 2022-11-14 | $604.00K derived: sum of 2 quarters · filed 2022-11-14 | $904.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $301.00K 10-Q · filed 2022-08-15 | $602.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $301.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |